Current development and future prospects in chemotherapy of tuberculosis

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Current tuberculosis (TB) treatment regimens, typically lasting 6-9 months, face significant challenges in real-world application, leading to lower cure rates.
• Treatment success is markedly lower for multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains.
• There is a critical need for novel anti-TB drugs to simplify and shorten treatment durations for all forms of TB, including cases co-infected with HIV.

Purpose of the Study:

• To review the current landscape of tuberculosis treatment and its inherent limitations.
• To provide an update on the status of new anti-TB drug candidates currently undergoing clinical evaluation.
• To highlight ongoing research in novel compound discovery and alternative drug delivery systems for TB.

Main Methods:

• Review of existing literature on TB treatment efficacy and challenges.
• Analysis of the current pipeline of anti-TB drug candidates in clinical trials.
• Discussion of novel chemical entities and repurposed agents for TB treatment.

Main Results:

• A pipeline of eleven new anti-TB drug candidates from seven distinct classes is under clinical evaluation.
• These candidates include novel antibacterials, agents approved for other infections, and one agent with limited existing TB approval.
• This represents the first significant advancement in anti-TB drug development in over four decades.

Conclusions:

• The development of new anti-TB drugs is crucial for improving treatment outcomes, especially for drug-resistant TB and HIV-coinfected patients.
• The current pipeline offers hope for shorter, simpler, and more effective TB treatment regimens.
• Continued research into novel compounds and innovative drug delivery methods is essential for eradicating TB.